[ad_1]
Supernus Pharmaceuticals said on Monday the U.S. FDA declined to approve its drug-device combination to treat movement-related symptoms of Parkinson’s disease, sending its shares down 9% in early trade. This is the second time the regulator has refused to approve, dealing a…
[ad_2]